As neoadjuvant therapies become more potent, they create complex post-treatment tissue changes. This makes it incredibly difficult for pathologists—the ultimate arbiters of treatment success—to assess residual disease and surgical margins, leading to significant interpretation variability that directly impacts subsequent patient care.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The ALCHEMIST trial took a decade to reveal that adjuvant nivolumab offered no disease-free survival benefit. This lengthy timeline highlights the strategic advantage of neoadjuvant trial designs, which use surrogate endpoints like pathological response (PCR) to assess drug activity much more rapidly.

In neoadjuvant therapy, a patient's long-term outcome is better predicted by stopping tumor DNA shedding (ctDNA clearance) than by achieving pathologic complete response (pCR), the traditional gold standard. This redefines what constitutes a successful treatment response before surgery.

Actuate employed a master protocol that tested their drug alongside eight different standard-of-care chemotherapies in patients who had already failed them. This design efficiently demonstrated the drug's ability to reverse chemo-resistance across multiple histologies, informing their Phase 2 strategy.

To demonstrate its drug could overcome resistance, Actuate designed a trial where patients who had already failed a specific chemotherapy were given the exact same regimen again, but this time with Actuate's drug added. The resulting increased efficacy across eight different cancers provided powerful, direct proof of the drug's mechanism.

Data from trials like CheckMate 816 shows that achieving a Pathologic Complete Response (PCR) after neoadjuvant chemo-immunotherapy is a powerful early surrogate endpoint. Patients with PCR demonstrate markedly improved overall and event-free survival.

The presence of heterogeneous resistance mutations, some of which may be below detection limits, suggests a new strategy. Using a potent, broad-spectrum combination therapy upfront in the second-line setting, rather than sequential monotherapies, could eradicate more resistant clones and give patients a better chance at long-term survival or even a cure.

Keynote 671 data shows patients without a pathologic complete response after neoadjuvant chemoimmunotherapy have a 5-year event-free survival of only 43%. This outcome is comparable to standard chemoradiation (the PACIFIC regimen), questioning the benefit of pushing for surgery in poor responders.